333 related articles for article (PubMed ID: 18468571)
1. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
2. Advances in the early detection of ovarian carcinoma.
Garner EI
J Reprod Med; 2005 Jun; 50(6):447-53. PubMed ID: 16050569
[TBL] [Abstract][Full Text] [Related]
3. Update on ovarian cancer screening.
Munkarah A; Chatterjee M; Tainsky MA
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):22-6. PubMed ID: 17218847
[TBL] [Abstract][Full Text] [Related]
4. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract][Full Text] [Related]
5. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
6. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
Bast RC
Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
[TBL] [Abstract][Full Text] [Related]
7. New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound.
Dutta S; Wang FQ; Fleischer AC; Fishman DA
AJR Am J Roentgenol; 2010 Feb; 194(2):349-54. PubMed ID: 20093595
[TBL] [Abstract][Full Text] [Related]
8. Biomarker discovery in ovarian cancer.
Tung CS; Wong KK; Mok SC
Womens Health (Lond); 2008 Jan; 4():27-40. PubMed ID: 19072449
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of serum HE4 in endometriotic cysts.
Montagnana M; Lippi G; Danese E; Franchi M; Guidi GC
Br J Cancer; 2009 Aug; 101(3):548. PubMed ID: 19513069
[No Abstract] [Full Text] [Related]
10. Validation of serum biomarkers for detection of early-stage ovarian cancer.
Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
[TBL] [Abstract][Full Text] [Related]
11. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer screening and early detection.
Joyner AB; Runowicz CD
Womens Health (Lond); 2009 Nov; 5(6):693-9. PubMed ID: 19863472
[TBL] [Abstract][Full Text] [Related]
13. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
[TBL] [Abstract][Full Text] [Related]
14. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
15. Designing early detection programs for ovarian cancer.
Hartge P
J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
[No Abstract] [Full Text] [Related]
16. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
17. Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A; Ye B
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
[TBL] [Abstract][Full Text] [Related]
18. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
[TBL] [Abstract][Full Text] [Related]
19. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
20. HE4 as a biomarker for ovarian and endometrial cancer management.
Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
